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osting by EAbstract Objective: Monocyte chemoattractant protein-1 (MCP-1) is a member of CC chemokine
that plays an important role in the recruitment of monocytes/macrophages into renal tubulointer-
stitium. A biallelic A/G polymorphism at position 2518 in the MCP-1 gene was found to regulate
MCP-1 expression. MCP-1 and its A/G gene polymorphism have been implicated in the pathogen-
esis of some renal diseases. The aim of this study was to evaluate the role of circulating MCP-1 level
and the relevance of functional genetic variations of MCP-1 as early predictors of the development
of glomerulonephropathy (GN) in Egyptian patients.
Methods: This is a case control study that was conducted in 50 GN patients, 20 non-GN cases
and 20 ethnically matched healthy controls. MCP-1 serum level was detected by ELISA tech-
nique, while genotyping of polymorphisms in the MCP-1 genes was performed using a polymer-
ase chain reaction (PCR) followed by restriction fragment length polymorphism (RFLP)
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P, restriction fragment length
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160 A.M. Hassan et al.Results: High MCP-1 circulating levels and subsequently MCP-1 2518G polymorphism are
associated with the developing of nephropathy irrespective to the underlying etiology. MCP-1
serum level was signiﬁcantly high when compared with healthy controls (P= 0.0007) and
non-GN cases (P= 0.01). There was predominance of A allele at 2518 of MCP-1 gene in
healthy controls (87.5%) and non-GN cases (77.5%). The frequency of the 2518G MCP-1
polymorphism was signiﬁcantly higher in GN patients than in healthy controls (P< 0.0001;
OR= 15.6) and non-GN cases (P< 0.0001; OR = 7.7). Interestingly, homozygosity for G allele
plays the main role in such association.
Conclusion: A/G polymorphism in MCP-1 gene and subsequently high circulating MCP-1 level
confer a relevant role in the susceptibility to the development of nephropathy in the Egyptian
population denoting that MCP-1 system could be an early predictor of such renal complication.
 2010 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Chemokines form a superfamily of small, inducible and se-
creted chemotactic cytokines that play a crucial role in
inﬂammation, infection and immunity [1]. Monocyte chemoat-
tractant protein-1 (MCP-1) is secreted by a variety of cells as a
response to several proinﬂammatory stimuli [2,3]. MCP-1 trig-
gers activation, chemotaxis and transendothelial migration of
monocytes/macrophages to inﬂammatory lesions by interact-
ing with the membrane CC chemokine receptor 2 (CCR2) in
monocytes [4].
MCP-1 regulatory featuresare connectedwith the structureand
composition of the promoter region of theMCP-1 genemapped to
chromosome 17q11 [5]. A biallelic A/G polymorphism located at
position 2518 in the distal regulatory region regulates MCP-1
expression was detected [6]. Monocytes from individuals carrying
G allele at 2518 produce more MCP-1 than monocytes from
A/A homozygous subjects [7]. It was hypothesized that polymor-
phisms that inﬂuence the levels of chemokines might play a role
in the susceptibility to different diseases such as glomerulonephri-
tis, asthma and atherosclerosis [6–8].
Recently, glomerulonephropathy (GN) which is the most
common cause of end stage renal disease (ESRD) has been
considered as an inﬂammatory disease in which macrophage
inﬁltration into glomeruli is associated with the progression
of glomerular injury [1,9]. For the macrophage inﬁltration
MCP-1 plays a central role [10]. They could cause structural
damage through the release of proteolytic enzymes and oxygen
radicals and glomerular remodelling by the release of growth
factors and glomerular functional alterations by cytokines
[3,11,12] producing local chronic inﬂammatory response in
arterial walls, contributing to the progression of atherosclero-
sis, tubular atrophy and interstitial ﬁbrosis [13,14].
Of notice, diagnosis of GN is based on persistent albumin-
uria, arterial blood pressure elevation; a relentless decline in
glomerular ﬁltration rate (GFR) which is highly variable, so,
new tools are needed [15]. Although, increasingly weight of
clinical evidence indicates that MCP-1 system is a key factor
initiating the inﬂammatory process of glomerular insult
[16–18], the role of MCP-1 serum level (sMCP-1) and its gene
polymorphism in the development of nephropathy has not
been elucidated.
Given this background, and as early prediction of such re-
nal disturbance could prevent the complication as well as the
identiﬁcation of disease promoters is important for the crea-
tion of new powerful treatment modalities impeding the devel-opment of ESRD [15], the present study aimed to measure
circulating levels of MCP-1 in patients with GN of different
etiology, examines whether sMCP-1 levels were correlated with
such renal dysfunction and evaluates the inﬂuence of underly-
ing disease on MCP-1 level. Since GN represents a heteroge-
neous group of renal inﬂammatory diseases with similar
features, we also evaluated the role of MCP-1 polymorphism
in GN progression and whether different MCP-1 alleles are
linked to speciﬁc phenotypes.2. Subjects and methods
2.1. Study population
This case control studywas carried out at TantaUniversityHos-
pital between August 2008 and February 2009 prospectively.
Fifty selected patients suffering from GN, 20 normo-albumin-
uric patients and 20 healthy subjects with comparable age, sex
and male to female ratio were enrolled. GN cases were 21 men
and 29 women, aged 46.3 ± 7.4 years (range, 30–59 years).
The underlying disease in this groupwas type 2 diabetesmellitus
(DM) [19] in 21 patients (had not been previously treatedwith an
ACEIorAT-II receptor antagonists), hypertension [20] in 16 pa-
tients and lupus nephritis in 13 cases (assessed clinically accord-
ing to the renal Systemic Lupus ErythematosusDisease Activity
Index (SLEDAI) [21]. Nephropathy was diagnosed clinically by
the presence of persistentmicro-albuminuria (albumin excretion
rate [AER] 20–200 lg/min) and elevated bloodpressure (systolic
blood pressure >135 mmHg and/or diastolic blood pressure
>85 mmHg) [17].
Normo-albuminuric patients (8 males and 12 females; mean
age, 44.9 years; range 38–58 years) with AER< 20 lg/min
were used as non-GN controls. They included 9 patients with
type 2 DM, 6 patients with atherosclerosis and 5 patients with
Systemic Lupus Erythematosus (SLE) that was deﬁned accord-
ing to the American College of Rheumatology (ACR) criteria
[22]. Both GN and non-GN cases were recruited from those
attending the Nephrology Unit in Internal Medicine Depart-
ment for follow up.
Twenty healthy blood donor volunteers (9 males and 11 fe-
males; mean age, 48.4 years; range, 40–57 years) with compa-
rable age, sex and male to female ratio were served as a
healthy control group. They had no history of hypertension,
renal, cardiac or hepatic diseases. All participants gave written
informed consent after approval of the ethical committee.
Figure 1 Agarose gel electrophoresis for RFLP-PCR product of
MCP-1 gene, stained with ethiduim bromide. M represents DNA
marker. Lanes 2 and 5 represent homozygote A/A with single
234 bp band. Lanes 3, 6 and 7 represent heterozygote A/G with
234, 159 and 75 bp bands. Lanes 1 and 4 represent homozygote
G/G with 159 and 75 bp bands.
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2.2.1. Routine laboratory investigation
Patients and control group were subjected to a thorough his-
tory taking and complete clinical examination. Blood urea
nitrogen, serum creatinine, AER, fasting serum total choles-
terol, serum triglycerides, high-density lipoproteins, low-den-
sity lipoproteins, and urine analysis were performed.
2.2.2. MCP-1 serum level
MCP-1 serum level was detected with ELISA technique using
kit supplied by R&D systems, Minneapolis, USA according to
the manufacture instructions.
2.2.3. MCP-1 genotyping
The 2518 G/A polymorphism of the MCP-1 gene was deter-
mined using PCR-RFLP technique as described previously [23].
2.2.3.1. DNA extraction and ampliﬁcation. Genomic DNA was
extracted from EDTA blood by standard techniques using
QIA amp blood kit (Qiagen, Germany) according to the man-
ufacturer’s instruction. Ampliﬁcation was carried out in 50 ll
volume containing 300 ng genomic DNA, 0.1 lM of each pri-
mer (forward 50-TCT CTC ACG CCA GC ACT GAC C-30
and reverse 50-GAG TGT TCA CAT AGG CTT CTG-30),
200 lM of each dNTP, 3 mM of MgCl and 0.2 U of Taq Gold
polymerase (Life technology, USA). Ampliﬁcation was con-
ducted in Biometra, USA, thermal cycler under the following
conditions: one cycle of initial denaturation at 94 C for
4 min followed by 30 cycles of denaturation at 94 C for
45 s, annealing at 61 C for 45 s, extension at 72 C for 45 s
then a ﬁnal extension cycle at 72 C for 7 min.
2.2.3.2. MCP-1 gene polymorphism. The ampliﬁed PCR prod-
ucts were digested with the addition of 2 U PvuII restrictive en-
zyme (New England BioLab, Beverly, MA, USA) overnight at
37 C. The digested products were separated by electrophoresis
through 3% agarose gel stained with ethidium bromide. Upon
digestion with Pvu II of the ampliﬁed DNA product (size
234 bp), two fragments of 159 and 75 bp were produced when
the polymorphic site was present (G at position2518) (Fig. 1).
2.3. Statistical analysis
The statistical software package SPSS 15 was used for statisti-
cal calculations. Data are presented as mean ± SD for contin-
uous variables and as proportions for categorical variables.
Comparisons of means between 2 groups were analyzed by
using the Student unpaired T-test while comparisons of meansTable 1 Clinical characteristics of patients and control groups.
Group No. Age (year) M:F
Controls 20 48.4 ± 5.4 9:11
Non-GN group 20 44.9 ± 9.1 8:12
GN group 50 46.3 ± 7.4 21:29
Non-GN: non-glomerulonephrotic; GN: glomerulonephrotic; M:F: male:
Data are expressed as mean ± SD.
a ANOVA test.
b P< 0.0001.among 3 groups were performed using one-way ANOVA test.
The allele and genotype frequencies among cases and controls
were compared by Fisher exact test and odds ratio with 95%
CI. Two-tailed P-value of 60.05 was considered signiﬁcant.
Pearson’s correlation coefﬁcient was used to detect the rela-
tionship between sMCP-1 level and AER.
3. Results
3.1. Basic characteristics of the study population
Tables 1 and 2 summarize the basic characteristics of the study
population. There was a signiﬁcant increase in mean values of
systolic and diastolic blood pressure, TG, TC, LDL-C, serum
creatinine, and AER as well as a signiﬁcant decrease in mean
values of HDL-C and C clearance in GN patients compared
with control and normo-albuminuric groups. These changes
were related to the severity of their disease. Of notice, there
were no differences between subgroups of GN in any of the
previous parameters.
3.2. MCP-1 serum level in cases and controls
Circulating MCP-1 level increased in accordance with the
developing of nephropathy. The mean sMCP-1 concentration
was signiﬁcantly different (P= 0.001) among the studiedDuration (years) SBP (mmHg) DBP (mmHg)
– 117 ± 4 78 ± 3
14.6 ± 2.8 134 ± 3 84 ± 2
16.7 ± 5.3 167 ± 8a,b 93 ± 3a,b
female; SBP: systolic blood pressure; DBP: diastolic blood pressure.
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162 A.M. Hassan et al.groups. Inter group analysis revealed that 30% (P= 0.0007)
and 20% (P= 0.01) increase in sMCP-1 levels in patients with
GN (65.8 pg/ml) compared with either of the control and nor-
mo-albuminuric groups (50.5 pg/ml and 54.4 pg/ml), respec-
tively. In contrast, no signiﬁcant difference has been
observed in sMCP-1 values between normo-albuminuric and
the control groups (Table 3) as well as there was no signiﬁcant
difference between GN subgroups (P> 0.05) (Table 4).
Interestingly, levels of sMCP-1 tended to be positively cor-
related (r= 0.87, P< 0.001) with AER in GN group (Fig. 2).
On the other hand, although a tendency of positive correlation
between sMCP-1 and TG was found, a negative correlation be-
tween sMCP-1 and HDL-C also existed, in both cases the cor-
relation did not achieve statistical signiﬁcance. Meanwhile, we
did not ﬁnd correlation between sMCP-1 and age, duration of
the disease, TG, TC, DBP and SPB (data not shown).3.3. Polymorphism frequency distribution between the case and
the control groups
The distribution of wild (AA) and mutant (AG/GG) genotypes
was 80% and 20% in control group with low frequency of GG
genotype (5%) and G allele (12.5%). We found nearly similar
distribution in genotype and allele frequencies in normo-albu-
minuric cases. The exact test of population distribution indicated
that the distributions of MCP-1G allele frequencies were signiﬁ-
cantly higher in GN-patients (69%) compared to both control
subjects (12.5%, P< 0.0001, OR= 15.6) and normo-albumin-
uric cases (22.5%, P< 0.0001, OR= 7.7) (Table 5).
The genotype frequency showed signiﬁcant increase in mu-
tant genotypes (80% vs. 20%, P < 0.0001, OR = 16) with the
predominance of homozygote mutant (GG) genotype (58% vs.
5%, P< 0.0001, OR = 26.2) in GN patients group compared
with healthy controls. Similarly, there is signiﬁcant increase in
mutant genotypes (80% vs. 35%, P= 0.0006, OR= 7.4) with
the predominance of homozygote mutant (GG) genotype
(58% vs. 10%, P= 0.0004, OR= 12.4) in GN group com-
pared to normo-albuminuric group. Moreover, the higher
OR in homozygotes (26.2) than in heterozygotes (1.6) in com-
paring GN cases with other two groups suggests a dominant
mode of action of the homozygote MCP-1 2518 polymor-
phism in the development of GN (Table 5).
By analyzing the link of different MCP-1 alleles and geno-
types to speciﬁc disease background, no signiﬁcant difference
in the allele or genotype frequencies between different causes
of GN with P values of >0.05 was found (Table 6).
3.4. Relationship between GN, MCP-1 serum level, and MCP-1
gene 2518 G/A polymorphism
Analyzing sMCP-1 level within different genotypes reveals po-
sitive association between high sMCP-1 level andMCP-1 genet-
ic mutation in controls, GN cases and non-GN patients. In
hetero- and homo-zygote individuals, sMCP-1 levels were in-
creased 1.6 times in GN patients and 1.3 times in both controls
and normo-albuminuric cases. No signiﬁcant difference in
sMCP-1 level in subjects carrying wild genotype between all
studied groups (P= 0.128). Additionally, no signiﬁcant differ-
ence in sMCP-1 level in mutant genotype was detected on com-
paring healthy controls with normo-albuminuric cases
(P= 0.452). In contrary, there was signiﬁcant increase in
Table 3 Comparison of MCP-1 serum level between healthy control, non-GN and GN groups.
Variable Controls (n= 20) Non-GN group (n= 20) GN group (n= 50)
MCP-1 (pg/ml)
Range 30–90 34–102 43–120
Mean ± SD 50.5 ± 13.4 54.4 ± 16.7 65.8 ± 17.2
F (P) 7.7 (0.001)a
T-test (P)
Controls Non-GN 0.8 (0.4) Non-GN & GN
2.5 (0.01)GN 3.6 (0.0007)a
Non-GN: non-glomerulonephropathy; GN: glomerulonephropathy.
a P< 0.05 is signiﬁcant.
Table 4 Serum level of MCP-1 in glomerulonephrotic (GN)
group.
Variable GN group
DM (n= 21) HT (n= 16) LN (n= 13)
MCP-1 (pg/ml)
Range 46–115 45–120 43–110
Mean ± SD 66.8 ± 16.5 66.7 ± 16.6 65.9 ± 20.8
F (P) 0.011 (0.9)
T-test (P)
DM HT 0.02 (0.9) HT & NA
0.115 (0.9)LN 0.14 (0.8)
DM: diabetes mellitus; HT: hypertension; LN: lupus nephritis.
r=0.876      P-value<0.001*
MCP-1 (pg/ml)
12010080604020
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R
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Figure 2 Correlation between sMCP-1 level and AER in 50 GN
cases. Signiﬁcant positive correlation was detected.
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the same genotype in control and normo-albuminuric group
with a P-value of <0.0001 (Table 7). Interestingly, we found
that the serum level of MCP-1 was signiﬁcantly increased with
mutant genotype in GN group regardless of the cause of GN
(Table 8).4. Discussion
In this study we demonstrated that up-regulation of sMCP-1 is
probably involved in the development of GN. This concept is
based on: (1) sMCP-1 levels were signiﬁcantly elevated in GNpatients compared to the healthy controls, and normo-albu-
minuric cases, (2) MCP-1 serum level was nearly similar within
GN sub-groups and (3) signiﬁcant positive correlation was de-
tected between GN group and AER. Thus, we suggest that this
marker reﬂects the progression of albuminuria in nephropathy
and could be a predictor of the development of GN irrespec-
tive of the underlying etiology.
The role of circulating MCP-1 in renal damage in different
glomerular diseases, such as DM [13], SLE [7], IgA nephropathy
[24] and polycystic kidney [25] has been intensively investigated.
Although many studies have focused on the association between
circulating or urinaryMCP-1 level and such renal disorders, only
few of them were concerned with its role in nephropathy which
seems to be controversial. Of these, Chiarelli et al. [26] high-
lighted a possible role of circulating MCP-1 in the development
of early nephropathy in patients with type 1 diabetes. A result
that was further supported by Takebayashi et al. [13] who sug-
gested that serum MCP-1 correlates not only with macroalbu-
minurea, but also with UAE in their type 2 diabetic patients.
This is explained by the pivotal role played by increased MCP-
1 production due to stimulation by cytokines [27] and exposure
to urinary proteins [28] in the progressive tubulointerstitial dam-
age which is thought to be the common pathological ﬁnding
resulting in ESRD in spite of causes of renal damages [29].
On the other hand, Kiyici et al. [3] demonstrated that serum
MCP-1 levels were signiﬁcantly increased in type 1 diabetic pa-
tients but not correlated with development of nephropathy.
Ihm et al. [30] reported that peripheral blood mononuclear
cells produced more MCP-1 in patients with or without dia-
betic nephropathy than cells from controls. This result was ex-
plained by Ha et al. [31] who verify that high glucose-induced
generation of reactive oxygen species (ROS) and protein kinase
C (PKC) activation seem to be involved in NF-aB activation
and subsequently inﬂuence serum MCP-1 concentration.
Banba et al. [32] and Wada et al. [33] noticed that urine lev-
els, but not serum levels, of MCP-1 increased in accordance
with the extent of albuminuria in their studies on type 1 and
2 diabetic patients. Morii et al. [17] added that urine levels,
but not serum levels, of MCP-1 correlates with the develop-
ment of diabetic nephropathy. Interestingly, Qiu-yue and
Fen-qin concluded that both serum and local MCP-1 had an
impact on kidney affection a superior role of urinary MCP-1
as early predictor before appearance of proteinurea [1].
MCP-1 activates tubular epithelial cells leading to increase
in secretion of the proinﬂammatory cytokine interleukin-6
(IL-6) and expression of intracellular adhesion molecule -1
(ICAM-1) via Gi-protein, protein kinase C (PKC) and
Table 5 Distribution and comparison of 2518 A/G genotype and allele frequencies of MCP-1 gene in all studied groups.
Subject groups Genotypes frequency Alleles frequency
Wild Mutant
AA AG GG Total A G
Controls (n= 20): n (%) 16 (80) 3 (15) 1 (5) 4 (20) 35 (87.5) 5 (12.5)
Non-GN cases (n= 20) (vs. controls)
n (%) 13 (65)a 5 (25)a 2 (10)a 7 (35)a 31 (77.5)a 9 (22.5)a
GN cases (n= 50) (vs. controls)
n (%) 10 (20)b 11 (22) 29 (58)b 40 (80)b 31 (31)b 69 (69)b
OR (95% CI) 0.1 (0.02–0.2) 1.6 (0.4–6.5) 26.2 (3.3–211.7) 16 (4.4–58.5) 0.1 (0.02–0.2) 15.6 (5.6–43.6)
GN cases (n = 50) (vs. non-GN)
n (%) 10 (20)c 11 (22) 29 (58)c 40 (80)c 31 (31)c 69 (69)c
OR (95% CI) 0.1 (0.04–0.4) 0.8 (0.3–2.9) 12.4 (2.6–59.4) 7.4 (2.4–23.5) 0.1 (0.06–0.3) 7.7 (3.3–18)
Non-GN: non-glomerulonephropathy; GN: glomerulonephropathy.
OR: Odds ratio, 95% CI: 95% conﬁdence interval.
a Non-GN cases vs. controls by Fisher exact test, P> 0.05 (non signiﬁcant).
b GN cases vs. controls by Fisher exact test, P< 0.0001 (highly signiﬁcant).
c GN cases vs. non-GN cases by Fisher exact test, P 6 0.001 (signiﬁcant).
Table 6 Distribution of 2518 A/G genotype and allele frequency of MCP-1 gene in diseased groups.
DM (n= 21) HT (n= 16) LN (n= 13) P-valuea
n % n % n %
Genotype
AA 4 19 3 18.8 3 23.1 1
AG 4 19 4 25 3 23.1 0.913
GG 13 62 9 56.2 7 53.8 0.876
Allele
A 12 28.6 10 31.2 9 34.6 0.859
G 30 71.4 22 68.8 17 65.4 0.859
DM: diabetes mellitus; HT: hypertension; LN: lupus nephritis; AA: wild genotype; AG and GG: mutant genotype.
a By using Fisher-exact test.
164 A.M. Hassan et al.intracellular Ca2+ dependent mechanisms. MCP-1 activated:
(i) the transcription factor nuclear factor-jB (NF-jB), a tran-
scription factor involved in inﬂammatory and immune re-
sponses and (ii) activating protein-1 (AP-1) a transcription
factor involved in inﬂammatory and growth responses. Both
NF-kB and AP-1 were involved in the MCP-1 mediated
induction of IL-6 [34].
Another ﬁnding in this work was that G allele frequency was
signiﬁcantly higher in GN group than other two groups. This is
in agreement with the study done by Ye DQ et al. [35] and
Moon et al. [36] who found that the2518 G frequency is obvi-
ously over-represented in Asian, Mexican, Korean and Chinese
populations, reﬂecting variations between different ethnic pop-
ulations which probably has an impact on disease processes, or
a patient’s response to infections or drugs.
Finally, our results demonstrated that patient’s carriers for
the G allele especially the homozygotes were at increased risk
for GN with positive association between MCP-1 mutant
genotype and G allele and high serum MCP-1 level irrespective
of the underlying cause. These results suggest that G allele car-
riage is responsible for increased production of serum MCP-1
in our GN patients and predisposes to the development of
nephropathy rather than the occurrence of the disease itself.Human MCP-1 gene transcription appears to be under the
control of 2 distinct areas of the 50-ﬂanking region of the gene.
The distal regulatory region is located 1.8 through 2.7 kb up-
stream of the transcriptional start site. This segment contains
2 nuclear factor-jB binding motifs essential for cytokine
induction of MCP-1 expression. The 2518 A to G polymor-
phism might affect the transcriptional activity of this region
and is correlated with individual differences in monocyte
MCP-1 production [37,38].
Rovin et al. [37] suggested that the 2518 G allele produced
more MCP-1 in interleukin-1-stimulated peripheral blood
mononuclear cells, the effect of A/G MCP-1 gene polymor-
phism on MCP-1 production is controversial. Simeoni et al.
[38] showed that the presence of the 2518 G allele was asso-
ciated with decreased plasma MCP-1, decreased prevalence of
insulin resistance, and decreased risk of DM. Although, Kouy-
ama et al. failed to detect an association between MCP-1A/G
polymorphism and type 2 diabetes, they noticed that the
2518 AA genotype was associated with higher serum MCP-
1 concentration [39]. Kim et al. [40] also reported that urinary
excretion of MCP-1 was greater in AA homozygotes than in
other genotypes in Korean patients with lupus nephritis. Moon
et al. [36] added that carriage of 2518 A allele in the MCP-1
Table 7 Serum level of MCP-1 in different genotypes in the studied groups.
Studied groups MCP-1 (pg/ml) in diﬀerent genotypes T-test P-value
AA AG/GG
Controls
Range 30–55 41–90 2.8 0.013
Mean ± SD 45.3 ± 6.8 56.4 ± 9.1
Non-GN group
Range 34–60 46–102 3.1 0.006a
Mean ± SD 47.6 ± 8.2 62.3 ± 13.2b
GN group
Range 43–69 55–120 8.4 <0.0001a
Mean ± SD 51.8 ± 8.5 84.6 ± 11.5c,d
F 2.179 19.508
P 0.128 <0.0001a
Non-GN: non-glomerulonephropathy; GN: glomerulonephropathy; AA: wild genotype; AG/GG: mutant genotype.
a P< 0.05 is signiﬁcant.
b Comparing non-GN with controls, T-test (P-value) = 0.785(0.4526).
c Comparing GN with controls, T-test (P-value) = 4.739(0.000).
d Comparing GN with non-GN, T-test (P-value) = 4.636(0.000).
Table 8 Serum level of MCP-1 in different genotypes break down by GN etiology.
GN group MCP-1 (pg/ml) in diﬀerent genotypes T-test P-value
AA AG/GG
DM
Range 46–58 61–115 5.679 0.0001
Mean ± SD 51.7 ± 5.9 87.8 ± 12.2
HT
Range 45–59 65–120 4.626 0.0004
Mean ± SD 51.2 ± 6.1 89.4 ± 13.7
LN
Range 43–55 63–110 5.501 0.0002
Mean ± SD 49.3 ± 6.5 88.6 ± 11.6
F 0.139 0.060
P 0.873 0.942
DM: diabetes mellitus; HT: hypertension; LN: lupus nephritis.
Circulating MCP-1 level and 2518 gene polymorphism as a marker of nephropathy development in Egyptian patients 165gene was associated with the susceptibility of kidney failure in
Korean patients with type 2 DM. These inconsistent results
might be population-dependent and/or phenotype speciﬁc.
In conclusion, the present study implicates the role of circu-
latory MCP-1 and its 2518 G gene polymorphism as a pre-
dictor of the development of GN in Egyptian patients. As
MCP-1 plays an important role in the stimulation of the
inﬂammatory inﬁltrate, and probably, it might also have
immunomodulatory effects, thus, we suggest that preventing
MCP-1 secretion or inhibiting its effects might be a useful
approach for the research on new therapeutic tools.Conﬂicts of interest
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